Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$110B
P/E
30
Revenue Growth
+12.0%
Gross Margin
N/A
ROE
N/A
About Vertex Pharmaceuticals
Listed on the NASDAQ, Vertex Pharmaceuticals operates as a large-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. Dominant cystic fibrosis franchise with expanding pain and gene therapy pipeline. Valued at 30x trailing earnings with a $110B market capitalization, the business is characterized by consistent top-line gains, reporting +12% revenue change year-over-year.
Expert Coverage
Unlock Full VRTX Analysis
Expert analysis and coverage for Vertex Pharmaceuticals
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-08
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B